The fate of the hydrolysis products of thalidomide in the pregnant rabbit.
1. The fate in the pregnant New Zealand White rabbit of oral doses of four (14)C-labelled hydrolysis products of thalidomide, namely alpha-(o-carboxybenzamido)-glutarimide, 2-phthalimidoglutaramic acid, 2-phthalimidoglutaric acid and 2-(o-carboxybenzamido)glutaramic acid, administered on the 192nd hour of pregnancy has been studied. 2. About 60-95% of the administered (14)C of each compound appears in the urine in 58hr. and the remainder is found in the faeces and in the gut and its contents. 3. Radioactivity is present in the plasma, liver, kidney, brain, muscle, fat and embryo. 4. The (14)C-labelled substances in the plasma and embryo consist of the unchanged compounds and their further hydrolysis products. 5. Since the above four thalidomide hydrolysis products are found in the rabbit conceptus together with their further hydrolysis products after their oral administration to the pregnant rabbit, it appears that the teratogenic activity of thalidomide is due to the compound itself rather than to one or more of its hydrolysis products.
D000273:Adipose Tissue / Q000032:analysis; D000818:Animals; D001774:Blood Chemical Analysis; D001923:Brain Chemistry; D002247:Carbon Isotopes; D004064:Digestive System / Q000032:analysis; D004622:Embryo, Mammalian / Q000032:analysis*; D005243:Feces / Q000032:analysis; D005260:Female; D005977:Glutarates / Q000378:metabolism*; D007668:Kidney / Q000032:analysis; D008099:Liver / Q000032:analysis; D009132:Muscles / Q000032:analysis; D011247:Pregnancy; D011270:Pregnancy, Animal; D011817:Rabbits; D013792:Thalidomide / Q000378:metabolism*; D014556:Urine / Q000032:analysis
D002247:Carbon Isotopes; D005977:Glutarates; D013792:Thalidomide